Nordion provides outlook for 2012

01/11/2012 | MolecularImaging.net

Although 2011 revenue was up overall, Nordion is anticipating a decline in its reactor isotopes revenue for fiscal year 2012. The company expects volumes of molybdenum-99 to remain the same, but anticipates competition will drive prices down. Nordion estimates 2012 quarterly revenue for cyclotron isotopes to be at $3.5 million per quarter.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC